Compare AU
Compare CURE vs. VTS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Vanguard US Total Market Shares Index ETF (VTS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | VTS | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 82 | 2,894 |
Median incremental investment | $619.50 | $1,270.59 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $5,193.65 |
Average age group | > 35 | > 35 |
Key Summary
CURE | VTS | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | Vanguard U.S. Total Market Shares Index ETF (ASX: VTS) seeks to track the performance of the CRSP US Total Market Index before account fees, expenses and taxes. The index tracks the large, mid, small and micro-cap stocks on the US stock market, thus representing nearly 100% of the investable US stock market. |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | Apple Inc. (5.56 %) Microsoft Corp. (4.68 %) Amazon.com Inc. (2.06 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Information Technology (25.02 %) Health Care (15.04 %) Financials (10.84 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (99.41 %) Switzerland (0.25 %) Canada (0.12 %) |
Management fee | 0.45 % | 0.03 % |
Key Summary
CURE | VTS | |
|---|---|---|
Issuer | Global X | Vanguard |
Tracking index | S&P Biotechnology Select Industry | CRSP U.S. Total Market Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.03 % |
Price | $49.94 | $472.15 |
Size | $38.065 million | $30.252 million |
10Y return | N/A | 257.39 % |
Annual distribution yield (5Y) | 4.24 % | 1.34 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 08/05/2009 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | VTS | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 82 | 2,894 |
Median incremental investment | $619.50 | $1,270.59 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $5,193.65 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | VTS | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | VTS |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |